Roche Starts Phase II Trial of Alzheimer’s Drug RG6434
Genentech and Roche are initiating the Phase II TARBELA-AD trial of investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease.
Story updates
06:02:08 AM UTC
SquawkNews
Roche is initiating TARBELA-AD, a Phase II trial evaluating investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease. The company also plans to present Alzheimer’s portfolio data at CTAD 2026.Material DetailsContext by AI AnalystThis is an early-stage pipeline update wit…